Author Manuscript Published OnlineFirst on January 28, 2014; DOI: 10.1158/0008-5472. 3 ABSTRACT Impairment of double-stranded DNA break (DSB) repair is essential to many cancers. However, while mutations in DSB repair proteins are common in hereditary cancers, mechanisms of impaired DSB repair in sporadic cancers remain incompletely understood. Here, we describe the first role for a long noncoding RNA (lncRNA) in DSB repair in prostate cancer. We identify PCAT-1, a prostate cancer outlier lncRNA, which regulates cell response to genotoxic stress. PCAT-1 expression produces a functional deficiency in homologous recombination (HR) through its repression of the BRCA2 tumor suppressor, which, in turn, imparts a high sensitivity to small molecule inhibitors of PARP1. These effects reflected a post-transcriptional repression of the BRCA2 3'UTR by PCAT-1. Our observations thus offer a novel mechanism of "BRCA-ness" in sporadic cancers.
INTRODUCTION
The uncontrolled accumulation of double-stranded DNA breaks (DSBs) represents a putative Achilles heel for cancer cells, since these lesions are toxic and their repair requires re-ligation of disrupted genetic material (1) (2) (3) . Several mechanisms, such as non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ) and homologous recombination (HR), contribute to DSB repair and are employed variously during cell cycle depending on whether a specific DSB harbors either large, small, or no stretches (NHEJ, MMEJ, and HR, respectively) of complementary DNA sequences on the two fragments of broken DNA (4) . In particular, the lethality of excess DSBs has been exploited for the therapeutic treatment of hereditary breast and ovarian cancers harboring BRCA1/2 mutations, which leads to defective HR and increased DSBs (5) . These cancers exhibit synthetic lethality when treated with small molecule inhibitors of the PARP1 DNA repair enzyme, whose inhibition prevents a second method of DNA repair and leads to gross collapse of cellular DNA maintenance (6) (7) (8) .
Recently, long noncoding RNAs (lncRNAs) have emerged as new layer of cell biology (9) , contributing to diverse biological processes. In cancer, aberrant expression of lncRNAs is associated with cancer progression (9, 10) , and overexpression of oncogenic lncRNAs can promote tumor cell proliferation and metastasis through transcriptional regulation of target genes (11) (12) (13) . Recent studies have also identified lncRNAs induced by genotoxic stress as well as involved in the repair of DNA damage (14, 15) ; however, the role of lncRNAs in the regulation of DSB repair remains unclear.
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Author Manuscript Published OnlineFirst on January 28, 2014; DOI: 10.1158/0008-5472.CAN- Here, we report the characterization of PCAT-1 as a prostate cancer lncRNA implicated in the regulation of DSB repair. We find that PCAT-1 represses the BRCA2 tumor suppressor gene, leading to downstream impairment of HR. Importantly, PCAT-1 expressing cells exhibit a BRCA-like phenotype, resulting in cell sensitization to PARP1 inhibitors. In human prostate cancer tissues, high PCAT-1 expression predicts for low BRCA2 expression, supporting our observations in model systems. To our knowledge, this report is the first to demonstrate a role for lncRNAs in the regulation of DSBs in prostate cancer and suggests a new mechanistic basis for impaired HR in this disease.
MATERIALS AND METHODS
For full details on methodology, please refer to the Supplementary Information for a complete Materials and Methods section. 
Patient samples

Cell lines
All cell lines were obtained from the American Type Culture Collection (Manassas, VA).
Cell lines were maintained using standard media and conditions. Du145-derived cell lines were maintained in DMEM supplemented with 10% FBS (Invitrogen) and 1% penicillin-streptomycin (Invitrogen) in a 5% CO 2 cell culture incubator. RWPE-derived cell lines were maintained in KSF (Invitrogen) supplemented with Bovine Pituitary Extract, Epidermal Growth Factor and 1% penicillin-streptomycin in a 5% CO 2 cell culture incubator. LNCAP-derived and PC3-derived were maintained in RPMI 1640 (Invitrogen) supplemented with 10% FBS and 1% penicillin-streptomycin in a 5% CO 2 cell culture incubator.
PC3 cells containing the GFP HR assay construct were generated as described previously (16, 17) .
PCAT-1 or control-expressing cell lines were generated by cloning PCAT-1 or control LacZ into the pLenti6 vector (Invitrogen). After confirmation of the insert sequence, lentiviruses were generated at the University of Michigan Vector Core and transfected into RWPE or Du145 cells. Stably-transfected cells were selected using blasticidin (Invitrogen). Author Manuscript Published OnlineFirst on January 28, 2014; DOI: 10.1158/0008-5472.CAN-13-3159 lentiviral constructs for 48 hours. GFP+ cells were drug-selected using 1 ug/mL puromycin. PCAT-1 shRNAs were customed generated by Systems Biosciences using the following sequences: shRNA 1 GCAGAAACACCAAUGGAUAUU; shRNA 2 AUACAUAAGACCAUGGAAAU.
To ensure cell identity, all cell lines were used for fewer than 6 months after resuscitation and confirmed by genotyping after resuscitation. DNA samples were diluted to 0.10ng/ul and nine genotyping loci (D3S1358, D5S818, D7S820, D8S1179, D13S317, D18S51, D21S11, FGA, vWA and the Amelogenin locus) were analyzed by the University of Michigan DNA Sequencing Core using the Profiler Plus PCR Amplification Kit (Applied Biosystems, Foster City, CA).
Cell line assays
LNCaP, Du145, PC3, and RWPE cell lines were obtained from the American Type Culture Collection (ATCC) and maintained in standard conditions. Stable overexpression and knockdown cell lines were generated with lentiviral constructs with blasticidin or puromycin selection as appropriate. RNA isolation and cDNA synthesis were performed according to standard protocols. Quantitative PCR was performed with Power SYBR Green Mastermix on an Applied Biosystems 7900HT Real-Time PCR system. Author Manuscript Published OnlineFirst on January 28, 2014; DOI: 10.1158/0008-5472. according to standard protocols; RAD51 and γ-H2AX staining was performed 6 hours or 24 hours post-treatment, respectively.
Luciferase Assays
The indicated cell lines were transfected with full length BRCA2 luciferase constructs as well as pRL-TK vector as internal control for luciferase activity. Following 2 days of incubation, the cells were lysed and luciferase assays conducted using the dual luciferase assay system (Promega, Madison, WI, USA). Each experiment was performed in quadruplicate.
Immunoblot Analysis
Cells were lysed in RIPA lysis buffer (Sigma, St. Louis, MO) and briefly sonicated for For immunoblot densitometry, the densitometric scan of the immunoblots was performed using ImageJ. Three replicate experiments were quantified for the final analysis.
Xenograft assays
Xenograft experiments were performed according to University of Michigan-approved protocols and conform to their relevant regulatory standards. 
I-SceI Homologous Recombination Assay
We followed previously described protocols (16) . Briefly, PC-3 cells with a single copy of DR-GFP were transfected with empty vector control or PCAT-1. PCAT-1 transfected cells were infected with adenovirus-encoded I-SceI (adeno-I-SceI) at an MOI of 1000.
Cells were harvested 3 days after infection and subjected to flow cytometry analysis for the GFP-positive cell population.
Statistical analyses for experimental studies
All data are presented as means ± standard deviation or S.E.M, as indicated. All experimental assays were performed in duplicate or triplicate. Statistical analyses shown in figures represent Fisher's exact tests or Student's t-tests, as indicated.
RESULTS
PCAT-1 regulates BRCA2 levels and homologous recombination
We previously reported the systematic nomination of lncRNAs associated with prostate cancer, termed Prostate Cancer Associated Transcripts (PCATs) (10) . Among these, we noted that PCAT-1 expression was a prostate cancer outlier associated with low levels of BRCA2. We therefore hypothesized that PCAT-1 mediated the repression of of PCAT-1 in LNCaP prostate cancer cells (which harbor high endogenous levels of PCAT-1 expression) (Fig. 1A, left) .
Western blot analysis of these three isogenic models uniformly revealed strong downregulation of BRCA2 protein levels in RWPE and Du145 prostate cells and upregulation of BRCA2 in LNCaP sh-PCAT-1 cells (Fig. 1A, right) . To ensure that these observations were not restricted to cell line-based studies, we further confirmed an inverse relationship between PCAT-1 and BRCA2 in two independent cohorts of human prostate cancer samples. Using 58 prostate cancer tissues and 20 prostate cancer xenografts derived from human specimens, we found that increasing PCAT-1 expression correlated with decreased BRCA2 expression ( Fig. 1B and Supplementary Fig. S1A ).
Together, these data suggest that PCAT-1 expression antagonizes BRCA2 expression.
Importantly, BRCA2 inactivation impairs HR of DSBs and serves as a predictive biomarker for response to treatment with inhibitors of the PARP1 DNA repair enzyme through synthetic lethality that results from joint inactivation of two DNA repair pathways (HR via BRCA2 inactivation, and base excision repair via PARP1 inhibition). Accordingly, treatment of our isogenic cell lines with either a PARP1 inhibitor (Olaparib or ABT-888) or radiation, resulted in modulation of RAD51 foci formation, which is a component of the HR pathway and a marker for engagement of the HR machinery (18) .
Specifically, PCAT-1 overexpression decreased RAD51 foci formation post-therapy and PCAT-1 knockdown increased RAD51 foci formation post-therapy in prostate ( Fig. 1C and Supplementary Fig. S1B-D) . We further used a well-characterized HR assay, in which cells employ HR to recombine an I-SceI-cut plasmid to produce GFP signaling (16) , to evaluate the function of PCAT-1 on HR directly. We found that transient 1D and Supplementary Fig. S2A-D) . Of note, PCAT-1 expression does not show substantial change following induction of DNA damage via radiation ( Supplementary   Fig. S2E ).
PCAT-1 expression impairs DNA damage repair
Because PCAT-1 impairs HR, genotoxic stress of PCAT-1-expressing cells should lead to an accumulation of DSBs, which can be visualized using gamma-H2AX (γH2AX) foci, a marker of double-stranded DNA breaks that have not been repaired (4) . To test this, we treated our isogenic Du145 and LNCaP cell line models with Olaparib, ABT-888, or radiation. As predicted, PCAT-1 overexpression in Du145 led to an increase in γH2AX foci under stress conditions ( Fig. 2A, B) , indicating that PCAT-1 impairs DSB repair in these cells. Similarly, LNCaP cells with PCAT-1 knockdown displayed decreased levels of γH2AX foci ( Fig. 2A, B) . Immunoblot analysis of γH2AX protein abundance in these cells following genotoxic stress confirmed a downregulation of γH2AX with knockdown of PCAT-1 and upregulation of γH2AX with overexpression of PCAT-1 (Supplementary Fig. S3 ).
Finally, we also evaluated the ability for our isogenic cell lines to sustain growth in clonogenic survival assays, a gold-standard assay for cell viability following genotoxic stress, after treatment of cells with PARP1 inhibition or radiation. We found that PCAT-1 expression led to decreased cell survival in Du145 and RWPE cells, whereas PCAT-1 knockdown increased LNCaP cell survival, in these assays (Supplementary Fig. S4 ). 
To exclude a regulatory relationship between PCAT-1 and other major actors in DNA damage, we performed analysis of XRCC1 (base excision repair pathway), XRCC3 (HR), XRCC4 (NHEJ), Ku70 (NHEJ), Ku80 (NHEJ), and BRCA1 (multiple pathways) in our in vitro models, which showed no change in protein abundance upon modulation of PCAT-1 (Supplementary Fig. S5A ). Together, these data indicate that PCAT-1 expression may impart cell sensitivity to genotoxic stress by decreasing the HR response through downregulation of BRCA2. (Fig. 3A, left and Supplementary Fig. S5B-D) .
PCAT-1 expression leads to increased cell death following genotoxic stress
This change in cell sensitivity to PARP1 inhibitors was striking, with a five-fold change in the IC50 for LNCaP and Du145 cells (Fig. 3A, right and Supplementary Fig. S6 ).
Similar results were observed in RWPE cells overexpressing PCAT-1 ( Supplementary   Fig. S7 ).
To ensure that these effects were dependent on BRCA2, we according to the efficiency of the BRCA2 knockdown (Fig. 3B) . We further observed reduced RAD51 foci post-treatment following BRCA2 knockdown in LNCaP shPCAT-1 cells as well (Supplementary Fig. S8 ). To exclude a role for altered cell cycle distributions in these phenotypes, we performed flow cytometry, which demonstrated no change in cell cycle in our model systems (Supplementary Fig. S9 ).
PCAT-1 expression leads to decreased in vivo tumor growth following PARP inhibition
To evaluate the contribution of PCAT-1 to PARP inhibitor response in vivo, we generated xenografts of Du145 cells expressing either empty vector control or PCAT-1.
We observed that Du145-PCAT-1 cells grew significantly more rapidly in severe combined immunodeficient (SCID) mice, consistent with our previous findings that (Fig. 3C) (10) . Moreover, Du145-PCAT-1 xenografts showed marked susceptibility and tumor regression following intraperitoneal (IP) administration of Olaparib, whereas Du145-control cells showed only a subtle change in growth while the drug was administered, indicating that the background effect of Olaparib therapy-possibly due to its effects on other members of the PARP family (19)-is small (Fig. 3C) . Mice in all groups of treatment maintained their body weights and showed no evidence of weight loss (Supplementary Fig. S10A ).
PCAT-1 accelerates prostate cell proliferation in vitro
Importantly, Du145 xenografts retained both PCAT-1 expression and BRCA2 repression (Fig. 3D) . To investigate PCAT-1 signaling under control-treated (DMSO) and Olaparib-treated conditions, we also observed in vivo upregulation of PCAT-1-induced target genes (TOP2A, E2F8, BIRC5, and KIF15) (Supplementary Fig. S10B Fig. S10C ) (10) .
confirmed in RWPE-PCAT-1 overexpressing cells (Supplementary
These data suggest that PCAT-1 is mechanistically linked to increased prostate cell sensitivity to PARP1 inhibitors via its repression of BRCA2 both in vitro and in vivo.
PCAT-1 does not operate via traditional lncRNA-mediated mechanisms
While many lncRNAs are noted to regulate gene transcription through epigenetic mechanisms (11, 13, 20) , we did not observe evidence for this possibility with PCAT-1.
While PCAT-1 regulated BRCA2 mRNA in vitro (Supplementary Fig. S11A) did not alter BRCA2 levels (Supplementary Fig. S11D ). To determine whether PCAT-1 may function in a manner more analogous to microRNAs, which regulate mRNA levels post-transcriptionally (22), we generated a luciferase construct of the BRCA2 3'UTR, which is 902 bps in length (Fig. 4A) .
PCAT-1 regulates BRCA2 post-transcriptionally
Surprisingly, we found that RWPE-PCAT-1 cells, but not control RWPE-LacZ cells, were able to directly repress the activity of the wild-type BRCA2 3'UTR construct (Fig. 4A) .
Supporting these data, we found that PCAT-1 was localized to the cell cytoplasm (Supplementary Fig. S12A) , and overexpression of PCAT-1 in Du145 cells significantly reduced the stability of endogenous BRCA2 mRNA, consistent with a post-transcriptional mechanism ( Supplementary Fig. S12B, C) .
To map a region of PCAT-1 required for repression of the BRCA2 3'UTR, we additionally generated a series of PCAT-1 deletion constructs and overexpressed these in RWPE cells (Fig. 4B and Supplementary Fig. S13A ). We generated these constructs to establish whether the 3' end of PCAT-1, which contains portions of ancestral transposase and Alu repeat elements (Fig. 4B) (10) , or the 5' end of PCAT-1, which consists of nonrepetitive DNA sequences, was required for BRCA2 repression. We observed that the 5' end of PCAT-1 was sufficient to downregulate the BRCA2 3'UTR luciferase signal as well as endogenous BRCA2 transcript levels (Fig. 4B, C) , and for this regulation, the first 250 bps of the PCAT-1 gene were required. By contrast, the 3' end of PCAT-1 was expendable. Importantly, the 5' end of PCAT-1 was similarly sufficient to sensitize RWPE cells to Olaparib treatment in vitro (Fig. 4D) . To rule out the possibility that Fig. S13B) .
Together, these results indicate that PCAT-1 overexpression is able to directly repress the activity of the BRCA2 3'UTR, and that this repression required the 5' end of PCAT-1.
DISCUSSION
To our knowledge, this is the first report of a lncRNA being involved in the DSB repair process in prostate cancer (Supplementary Fig. S14 ). These data are supported by a striking inverse correlation between PCAT-1 and BRCA2 expression in human prostate cancer samples. Our results expand the potential roles for lncRNAs in cancer biology and contrast strikingly with previous reports that lncRNAs operate epigenetically through chromatin modifying complexes (23, 24) . Indeed, epigenetic regulation likely represents only a one of numerous mechanisms for lncRNA function (12, 21, 25, 26) .
Supporting this notion, we do not observe compelling evidence that PCAT-1 functions in an epigenetic manner, but rather it may exhibit post-transcriptional regulation of its target genes.
Importantly, PCAT-1 is also predominantly cytoplasmic, and thus our work describes the first cytoplasmic prostate lncRNA to be associated with therapeutic response. Cytoplasmic lncRNAs are also less well explored than their nuclear counterparts, and our work sheds light onto the complex mechanistic regulation of cellular processes via cytoplasmic lncRNAs. However, PCAT-1 does exhibit a smaller degree of nuclear expression (see Supplementary Figure 12A ), which may account for our previous observation that PCAT-1 may associate with the nuclear Polycomb
Repressive Complex 2 (PRC2). As such, while our data directly support a role for 
PCAT-1 in the post-transcriptional regulation of BRCA2, we cannot fully exclude the possibility of additional regulation of BRCA2 at the transcriptional level at this time.
In addition, while the mechanism underlying PCAT-1 function remains incompletely understood, we were intrigued that the 5' portion of the PCAT-1 RNA, which is comprised of fully unique sequences, was critical for its regulation of BRCA2 mRNA whereas the embedded Alu element was not. While we did not identify a specific microRNA with high-confidence 7-mer complementary basepair matching to both this region of PCAT-1 and BRCA2 (data not shown), we speculate that alternative mechanisms of miRNA-like mismatch base pairing may contribute to PCAT-1-mediated regulation in a manner similar to the recently described networks of competing endogenous RNAs (ceRNAs) (27) . 
